Repligen Corporation | Stephens

Who We Are

What We Do

We provide investment banking, research, sales and trading, asset and wealth management, public finance, insurance, private capital, and family office services.

About Us

We are a family-owned financial services firm that values client relationships, long-term stability, and supporting the communities where we live and work.

The Stephens Story

The idea of family defines our culture, because each of us knows that our reputation is on the line as if our own name was on the door.


Our reputation as a leading independent financial services firm is built on the stability of our longstanding and highly experienced senior executives.

Impact Initiatives

We are committed to corporate philanthropy; economic and financial literacy advocacy; and diversity, equity, and inclusion initiatives.

Our Brand Ambassadors

Stephens is proud to sponsor the PGA TOUR, LPGA Tour, and PGA TOUR Champions careers, as well as applaud the philanthropic endeavors, of our Brand Ambassadors.

Making Connections

We host many highly informative meetings each year with clients, industry decision makers, and thought leaders across the U.S. and in Europe.

Back to transactions

Repligen Corporation

$250 Million 07/17/2019 Life Sciences & Medical Devices Complete
Public Companies
Show Tombstone

Transaction Details

  • On July 17, 2019, Repligen Corporation (“RGEN” or the “Company”) announced the pricing of concurrent underwritten offerings of 1,380,000 shares of RGEN common stock at a public offering price of $87.00 per share (the “Shares Offering”), and $250,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes Offering”)
  • The initial conversion rate for the Notes is 8.6749 shares of RGEN common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $115.28 per share, which represents a premium of approximately 32.5% over the public offering price of RGEN common stock in the concurrent Shares Offering of $87.00 per share)
  • Repligen intends to use net proceeds from the offerings to exchange, with a limited number of holders in privately negotiated transactions, approximately $92.0 million aggregate principal amount of its existing 2.125% Convertible Senior Notes due 2021 (the “2016 Notes”) for a combination of cash and RGEN shares, and to redeem the remaining $23.0 million of 2016 Notes
  • Repligen intends to use the remaining net proceeds for working capital and other general corporate purposes, including to fund possible future acquisitions
  • Stephens Inc. served as Joint Bookrunner on the Shares Offering, and as Co-Manager on the Notes Offering

About the company

Repligen Corporation (Nasdaq: RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional administrative and manufacturing operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.

Sources: Company filings.
  1. This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets, or developments referred to in the material. Information included in the material was obtained from sources w which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.

  2. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Stephens Inc.’s Equity Syndicate Desk, at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Equity Syndicate Desk, or from the Securities and Exchange Commission’s website at at the following links: and, and amended by A registration statement relating to these securities has been filed with the Securities and Exchange Commission. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the notice of its acceptance given after the effective date.